Tempest Therapeutics, Inc. (TPST)
Automate Your Wheel Strategy on TPST
With Tiblio's Option Bot, you can configure your own wheel strategy including TPST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TPST
- Rev/Share 0.1414
- Book/Share 3.2385
- PB 2.1306
- Debt/Equity 1.1771
- CurrentRatio 1.7024
- ROIC -1.8561
- MktCap 25408767.0
- FreeCF/Share -7.5947
- PFCF -0.9732
- PE -0.5295
- Debt/Assets 0.4074
- DivYield 0
- ROE -3.0551
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TPST | H.C. Wainwright | Buy | Neutral | -- | -- | April 10, 2025 |
| Downgrade | TPST | Scotiabank | Sector Outperform | Sector Perform | -- | -- | April 10, 2025 |
News
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.
Read More
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat combination therapy across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when compared to standard of care alone BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated …
Read More
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company's novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP).
Read More
About Tempest Therapeutics, Inc. (TPST)
- IPO Date 2012-11-12
- Website https://www.tempesttx.com
- Industry Biotechnology
- CEO Mr. Stephen R. Brady J.D., LLM
- Employees 24